Cygenics contract with DOD renewed
Wednesday, 16 February, 2005
Singapore-based Cygenics (ASX: CYN) has announced that the US Department of Defence had renewed its screening service contract with the company's US-based subsidiary Cytomatrix.
The renewal of the contract means that the company will receive the more than US$1 million remaining from the original contract which was valued at $1.684 million.
The DOD is using Cytomatrix's three-dimensional cell growth scaffold technology for the production of T cells that can be used to screen vaccine prototypes under development, allowing assessment of in vivo activity in an in vitro system.
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
Osteoarthritis study uncovers new genetic links, drug targets
The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...
How brain cells are affected by Tourette syndrome
US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...
